Immunome IMNM
NASDAQ IMNM
$18.04 +0.12 (+0.67%)
As of: Oct 21, 2026 · 2:49 PM EDT

Immunome (IMNM) EBITDA Margin (2020 - 2025)

Updated

Immunome (IMNM) posted EBITDA Margin of -3192.81% for FY2025, up 171.86 percentage points from -3364.67% in FY2024.

Analysis

Immunome (IMNM) EBITDA Margin (2020 - 2025) Analysis & Trends

  • Business Quant data shows IMNM's EBITDA Margin at -3364.67% in FY2024 (-2586.89 pp) and -777.79% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.71 Bn 1,105.29 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 617.55 Bn 536.07 Bn 17.26 Bn 35.95%
3 AbbVie 501.02 Bn 474.13 Bn 12.70 Bn 49.01%
4 Merck 368.18 Bn 322.56 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.89 Bn 261.88 Bn 11.24 Bn -
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn 33.11%
7 Amgen 236.60 Bn 191.99 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.55 Bn 164.75 Bn 6.22 Bn -124.26%
9 Pfizer 169.77 Bn 116.42 Bn 10.94 Bn 39.16%
10 Immunome 2.04 Bn 15.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,141.74%
Mar 31, 2025 -1,504.61%
Dec 31, 2024 -3,012.67%
Sep 30, 2024 -1,722.03%
Jun 30, 2024 -1,669.20%
Mar 31, 2024 -12,841.79%
Dec 31, 2023 -2,468.87%
Sep 30, 2023 -126.84%
Jun 30, 2023 -133.05%
Mar 31, 2023 -185.15%
Dec 31, 2022 -769,200.00%
Sep 30, 2022 -843,100.00%
Jun 30, 2022 -440,650.00%
Mar 31, 2022 -1,154,300.00%
Jun 30, 2020 -51,120.00%
API Access

Immunome EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IMNM&period=max&api_key=YOUR_API_KEY